Tags : Metastatic Castration-Resistant Prostate Cancer

Janssen’s Niraparib Receives the US FDA’s Breakthrough Therapy Designation for

Shots: The breakthrough designation is based on P-II GALAHAD study assessing Niraparib in adult patients with BRCA1/2 gene-mCRPC and DNA-repair gene defects (DRD) prior treated with androgen-receptor targeting therapies and docetaxel The FDA’s BT designation is granted to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious […]Read More

AstraZeneca and MSD’s Report Results of Lynparza in P-III PROfound

Shots: The P-III PROfound study involves assessing of Lynparza (olaparib) vs Enzalutamide/Abiraterone in men with mCRPC and have progressed on prior treatment with anti-cancer therapies with HRRm gene mutation The P-III PROfound study resulted in meeting its 1EPs i.e, improvement in radiographic PFS in men with mCRPC selected for BRCA1/2 or ATM gene mutations, safety […]Read More